1
|
Hocine S, Montagnon C, Reddy Vakiti J, Fourquez J, Hanessian S. Stereoselective Synthesis of Oxabicyclic Pyrrolidines of Medicinal Relevance: Merging Chemoenzymatic and Catalytic Methods. European J Org Chem 2020. [DOI: 10.1002/ejoc.202001276] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Affiliation(s)
- Sofiane Hocine
- Department of Chemistry Université de Montréal Station Centre-Ville, C.P. 6128 Montreal, QC H3C 3J7 Canada
| | - Claire Montagnon
- Department of Chemistry Université de Montréal Station Centre-Ville, C.P. 6128 Montreal, QC H3C 3J7 Canada
| | - Jithender Reddy Vakiti
- Department of Chemistry Université de Montréal Station Centre-Ville, C.P. 6128 Montreal, QC H3C 3J7 Canada
| | - Jean‐Marie Fourquez
- Institut de Recherches Servier CentEX Chemistry 125 chemin de ronde 78290 Croissy sur Seine France
| | - Stephen Hanessian
- Department of Chemistry Université de Montréal Station Centre-Ville, C.P. 6128 Montreal, QC H3C 3J7 Canada
| |
Collapse
|
2
|
Ogiyama T, Yonezawa K, Inoue M, Watanabe T, Sugano Y, Gotoh T, Kiso T, Koakutsu A, Kakimoto S, Shishikura JI. Discovery of a 1-isopropyltetrahydroisoquinoline derivative as an orally active N-type calcium channel blocker for neuropathic pain. Bioorg Med Chem 2015; 23:4624-4637. [DOI: 10.1016/j.bmc.2015.05.030] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2015] [Revised: 05/19/2015] [Accepted: 05/20/2015] [Indexed: 01/23/2023]
|
3
|
Ogiyama T, Yonezawa K, Inoue M, Katayama N, Watanabe T, Yoshimura S, Gotoh T, Kiso T, Koakutsu A, Kakimoto S, Shishikura JI. Discovery of an 8-methoxytetrahydroisoquinoline derivative as an orally active N-type calcium channel blocker for neuropathic pain without CYP inhibition liability. Bioorg Med Chem 2015; 23:4638-4648. [DOI: 10.1016/j.bmc.2015.05.053] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2015] [Revised: 05/28/2015] [Accepted: 05/29/2015] [Indexed: 01/05/2023]
|
4
|
Gleeson EC, Graham JE, Spiller S, Vetter I, Lewis RJ, Duggan PJ, Tuck KL. Inhibition of N-type calcium channels by fluorophenoxyanilide derivatives. Mar Drugs 2015; 13:2030-45. [PMID: 25871286 PMCID: PMC4413198 DOI: 10.3390/md13042030] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2015] [Revised: 03/18/2015] [Accepted: 03/26/2015] [Indexed: 12/26/2022] Open
Abstract
A set of fluorophenoxyanilides, designed to be simplified analogues of previously reported ω-conotoxin GVIA mimetics, were prepared and tested for N-type calcium channel inhibition in a SH-SY5Y neuroblastoma FLIPR assay. N-type or Cav2.2 channel is a validated target for the treatment of refractory chronic pain. Despite being significantly less complex than the originally designed mimetics, up to a seven-fold improvement in activity was observed.
Collapse
MESH Headings
- Analgesics, Non-Narcotic/chemical synthesis
- Analgesics, Non-Narcotic/chemistry
- Analgesics, Non-Narcotic/metabolism
- Analgesics, Non-Narcotic/pharmacology
- Anilides/chemical synthesis
- Anilides/chemistry
- Anilides/metabolism
- Anilides/pharmacology
- Binding, Competitive
- Calcium Channel Blockers/chemical synthesis
- Calcium Channel Blockers/chemistry
- Calcium Channel Blockers/metabolism
- Calcium Channel Blockers/pharmacology
- Calcium Channels, N-Type/chemistry
- Calcium Channels, N-Type/metabolism
- Calcium Signaling/drug effects
- Cell Line, Tumor
- Drug Design
- Fluorobenzenes/chemical synthesis
- Fluorobenzenes/chemistry
- Fluorobenzenes/metabolism
- Fluorobenzenes/pharmacology
- High-Throughput Screening Assays
- Humans
- Molecular Structure
- Molecular Targeted Therapy
- Nerve Tissue Proteins/antagonists & inhibitors
- Nerve Tissue Proteins/metabolism
- Neuralgia/drug therapy
- Neuralgia/metabolism
- Neurons/drug effects
- Neurons/metabolism
- Neurotoxins/chemistry
- Pain, Intractable/drug therapy
- Pain, Intractable/metabolism
- Structure-Activity Relationship
- omega-Conotoxin GVIA/chemistry
- omega-Conotoxin GVIA/metabolism
- omega-Conotoxin GVIA/pharmacology
Collapse
Affiliation(s)
- Ellen C Gleeson
- School of Chemistry, Monash University, Clayton VIC 3800, Australia.
- CSIRO Manufacturing Flagship, Clayton South, VIC 3169, Australia.
| | - Janease E Graham
- School of Chemistry, Monash University, Clayton VIC 3800, Australia.
- CSIRO Manufacturing Flagship, Clayton South, VIC 3169, Australia.
| | - Sandro Spiller
- School of Chemistry, Monash University, Clayton VIC 3800, Australia.
| | - Irina Vetter
- Institute for Molecular Bioscience, The University of Queensland, St Lucia QLD 4072, Australia.
| | - Richard J Lewis
- Institute for Molecular Bioscience, The University of Queensland, St Lucia QLD 4072, Australia.
| | - Peter J Duggan
- CSIRO Manufacturing Flagship, Clayton South, VIC 3169, Australia.
- School of Chemical and Physical Sciences, Flinders University, Adelaide SA 5042, Australia.
| | - Kellie L Tuck
- School of Chemistry, Monash University, Clayton VIC 3800, Australia.
| |
Collapse
|
5
|
Discovery of novel tetrahydroisoquinoline derivatives as orally active N-type calcium channel blockers with high selectivity for hERG potassium channels. Bioorg Med Chem 2014; 22:6899-907. [DOI: 10.1016/j.bmc.2014.10.020] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2014] [Revised: 10/16/2014] [Accepted: 10/16/2014] [Indexed: 01/08/2023]
|
6
|
Discovery and SAR of novel tetrahydropyrrolo[3,4-c]pyrazoles as inhibitors of the N-type calcium channel. Bioorg Med Chem Lett 2014; 24:2053-6. [DOI: 10.1016/j.bmcl.2014.03.062] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2014] [Revised: 03/18/2014] [Accepted: 03/19/2014] [Indexed: 11/17/2022]
|
7
|
Winters MP, Subasinghe N, Wall M, Beck E, Brandt MR, Finley MFA, Liu Y, Lubin ML, Neeper MP, Qin N, Flores CM, Sui Z. Discovery and SAR of a novel series of 2,4,5,6-tetrahydrocyclopenta[c]pyrazoles as N-type calcium channel inhibitors. Bioorg Med Chem Lett 2014; 24:2057-61. [PMID: 24726803 DOI: 10.1016/j.bmcl.2014.03.063] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2014] [Revised: 03/18/2014] [Accepted: 03/19/2014] [Indexed: 12/01/2022]
Abstract
A novel series of substituted 2,4,5,6-tetrahydrocyclopenta[c]pyrazoles were investigated as N-type calcium channel blockers (Cav2.2 channels), a chronic pain target. One compound was active in vivo in the rat CFA pain model.
Collapse
Affiliation(s)
- Michael P Winters
- Janssen Research and Development, LLC, 1400 McKean Rd., Spring House, PA 19477, USA.
| | - Nalin Subasinghe
- Janssen Research and Development, LLC, 1400 McKean Rd., Spring House, PA 19477, USA
| | - Mark Wall
- Janssen Research and Development, LLC, 1400 McKean Rd., Spring House, PA 19477, USA
| | - Edward Beck
- Janssen Research and Development, LLC, 1400 McKean Rd., Spring House, PA 19477, USA
| | - Michael R Brandt
- Janssen Research and Development, LLC, 1400 McKean Rd., Spring House, PA 19477, USA
| | - Michael F A Finley
- Janssen Research and Development, LLC, 1400 McKean Rd., Spring House, PA 19477, USA
| | - Yi Liu
- Janssen Research and Development, LLC, 1400 McKean Rd., Spring House, PA 19477, USA
| | - Mary Lou Lubin
- Janssen Research and Development, LLC, 1400 McKean Rd., Spring House, PA 19477, USA
| | - Michael P Neeper
- Janssen Research and Development, LLC, 1400 McKean Rd., Spring House, PA 19477, USA
| | - Ning Qin
- Janssen Research and Development, LLC, 1400 McKean Rd., Spring House, PA 19477, USA
| | - Christopher M Flores
- Janssen Research and Development, LLC, 1400 McKean Rd., Spring House, PA 19477, USA
| | - Zhihua Sui
- Janssen Research and Development, LLC, 1400 McKean Rd., Spring House, PA 19477, USA
| |
Collapse
|
8
|
Mechanistic insights into the analgesic efficacy of A-1264087, a novel neuronal Ca(2+) channel blocker that reduces nociception in rat preclinical pain models. THE JOURNAL OF PAIN 2013; 15:387.e1-14. [PMID: 24374196 DOI: 10.1016/j.jpain.2013.12.002] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/24/2013] [Revised: 11/05/2013] [Accepted: 12/02/2013] [Indexed: 01/06/2023]
Abstract
UNLABELLED Voltage-gated Ca(2+) channels play an important role in nociceptive transmission. There is significant evidence supporting a role for N-, T- and P/Q-type Ca(2+) channels in chronic pain. Here, we report that A-1264087, a structurally novel state-dependent blocker, inhibits each of these human Ca(2+) channels with similar potency (IC50 = 1-2 μM). A-1264087 was also shown to inhibit the release of the pronociceptive calcitonin gene-related peptide from rat dorsal root ganglion neurons. Oral administration of A-1264087 produces robust antinociceptive efficacy in monoiodoacetate-induced osteoarthritic, complete Freund adjuvant-induced inflammatory, and chronic constrictive injury of sciatic nerve-induced, neuropathic pain models with ED50 values of 3.0, 5.7, and 7.8 mg/kg (95% confidence interval = 2.2-3.5, 3.7-10, and 5.5-12.8 mg/kg), respectively. Further analysis revealed that A-1264087 also suppressed nociceptive-induced p38 and extracellular signal-regulated kinase 1/2 phosphorylation, which are biochemical markers of engagement of pain circuitry in chronic pain states. Additionally, A-1264087 inhibited both spontaneous and evoked neuronal activity in the spinal cord dorsal horn in complete Freund adjuvant-inflamed rats, providing a neurophysiological basis for the observed antihyperalgesia. A-1264087 produced no alteration of body temperature or motor coordination and no learning impairment at therapeutic plasma concentrations. PERSPECTIVE The present results demonstrate that the neuronal Ca(2+) channel blocker A-1264087 exhibits broad-spectrum efficacy through engagement of nociceptive signaling pathways in preclinical pain models in the absence of effects on psychomotor and cognitive function.
Collapse
|